Loading
A phase 2/3 trial testing Ivospemin in pancreatic ductal adenocarcinoma, now recruiting.
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer is a phase 2/3 interventional study registered as NCT05254171, led by Panbela Therapeutics, and recruiting on the registry. Official title: A Randomised, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma. Planned enrolment is 600 participants (estimated). The study started in 2022-08-08 and primary completion is expected in 2026-08-29. No results have been posted on ClinicalTrials.gov.